NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.